Saiama Waqar

Medicine & Life Sciences

1. Non-Small Cell Lung Carcinoma 100%
2. Small Cell Lung Carcinoma 43%
3. Lung Neoplasms 40%
4. Neoplasms 29%
5. Survival 24%
6. Circulating Tumor DNA 23%
7. Drug Therapy 23%
8. durvalumab 21%
9. Radiotherapy 19%
10. temsirolimus 18%
11. Platinum 17%
12. Squamous Cell Neoplasms 16%
13. Therapeutics 16%
14. Anaplastic Lymphoma Kinase 13%
15. Adjuvant Chemotherapy 13%
16. rovalpituzumab tesirine 11%
17. ensartinib 11%
18. Neoplasm Metastasis 11%
19. Etoposide 11%
20. Pemetrexed 10%
21. Mutation 10%
22. Medical Oncology 10%
23. Confidence Intervals 10%
24. Thorax 9%
25. Adenocarcinoma of Lung 9%
26. Maximum Tolerated Dose 9%
27. Carboplatin 9%
28. MP470 9%
29. Immunotherapy 8%
30. veliparib 8%
31. RRx-001 8%
32. TOR Serine-Threonine Kinases 8%
33. Human Influenza 7%
34. MLN 8237 7%
35. Neuroendocrine Tumors 7%
36. Epidemiology 7%
37. 130-nm albumin-bound paclitaxel 7%
38. Progression-Free Survival 6%
39. Vaccination 6%
40. palbociclib 6%
41. carfilzomib 6%
42. INCB018424 6%
43. Brain 6%
44. High-Throughput Nucleotide Sequencing 6%
45. olaparib 6%
46. Nausea 6%
47. Malignant Pleural Effusion 6%
48. Neuroendocrine Carcinoma 6%
49. Databases 6%